Cleared Traditional

KardiaAI (K181823) - FDA 510(k) Clearance

Class II Cardiovascular device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K181823 · AliveCor, Inc. · Cardiovascular device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Mar 2019
Decision
245d
Days
Class 2
Risk

K181823 is an FDA 510(k) clearance for the KardiaAI. Classified as Computer, Diagnostic, Programmable (product code DQK), Class II - Special Controls.

Submitted by AliveCor, Inc. (Mountain View, US). The FDA issued a Cleared decision on March 11, 2019 after a review of 245 days - an extended review cycle.

This device falls under the Cardiovascular FDA review panel, regulated under 21 CFR 870.1425 - the FDA cardiovascular device oversight framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Cardiovascular review framework, consistent with the majority of Class II 510(k) submissions.

View all AliveCor, Inc. devices

Submission Details

510(k) Number K181823 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received July 09, 2018
Decision Date March 11, 2019
Days to Decision 245 days
Submission Type Traditional
Review Panel Cardiovascular (CV)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
120d slower than avg
Panel avg: 125d · This submission: 245d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code DQK Computer, Diagnostic, Programmable
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 870.1425
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Cardiovascular devices follow this clearance model.

Regulatory Peers - DQK Computer, Diagnostic, Programmable

All 183
Devices cleared under the same product code (DQK) and FDA review panel - the closest regulatory comparables to K181823.
VIVO
K183195 · Catheter Precision, Inc. · Jun 2019
Edwards Pressure Cable
K191089 · Edwards Lifesciences, LLC · Jun 2019
AcQMap High Resolution Imaging and Mapping System
K190131 · Acutus Medical, Inc. · Apr 2019
RhythmAnalytics
K182344 · Biofourmis Singapore Pte., Ltd. · Mar 2019
EP-TRACER System
K183266 · Schwarzer Cardiotek GmbH · Mar 2019
QUANTIEN Measurement System
K183099 · St. Jude Medical (Now Abbott Medical) · Feb 2019